A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
一项随机、多中心 III 期研究,旨在评估单次给药依非马来诺格司亭α (F-627)(一种新型长效重组人粒细胞集落刺激因子)预防乳腺癌患者化疗引起的粒细胞减少症的疗效。
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-024-12892-5
Zhang, Qingyuan; Wang, Zhonghua; Yao, Wei; Wang, Shufang; Zhang, Gaochong; Chen, Jianmin; Hou, Qingsong; Li, Simon; Li, Hongsheng; Ye, Changsheng; Sun, Tao; Yang, Hongjian; Chen, Zhendong; Wang, Zhihong; Liu, Xiaoan; Geng, Cuizhi; Li, Xingrui; Zhang, Jin; Zheng, Hong; Shao, Zhimin